Neuromyelitis Optica clinical trials
23 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
- A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- Efgartigimod for the Treatment of Acute Optic Neuritis
- Stem Cell Ophthalmology Treatment Study II
- Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
- Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
- Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
- Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
- Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
- Biorepository and Registry for Plasma Exchange Patients
- Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
- Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
- MS-ResearchBiomarkerS
- Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD
- A Palliative Care Model Impact on Knowledge and Attitudes
- A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
- CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder
- Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
- Noninvasive Vagal Nerve Stimulation
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Neuromyelitis Optica” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.